-
Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies
•
Skyline Therapeutics, a Shanghai-based cell and gene therapy (CGT) developer, has announced encouraging preclinical study results for its AAV gene therapies, SKG0106 and SKG0201, targeting neovascular age-related macular degeneration (nAMD) and spinal muscular atrophy (SMA), respectively. SKG0106: A Novel AAV Therapy for nAMDSKG0106 is a self-developed novel AAV vector carrying…
-
Cellular Biomedicine Group Inc. and Janssen Biotech, Inc. Announce Global Collaboration for CAR-T Therapies
•
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG), emerging from a merger deal in February 2021, has announced a significant global collaboration and license agreement with US firm Janssen Biotech, Inc. (Janssen). The partnership is centered on the development and commercialization of C-CAR039, an anti-CD19 and CD20 bi-specific chimeric…
-
Chinese Authorities Launch Special Campaign to Combat Fraud in Medical Insurance
•
The National Healthcare Security Administration, Supreme People’s Procurator, Ministry of Public Security, Ministry of Finance, and National Health Commission have collaboratively released a special rectification work plan aimed at combating fraud and deception in the medical insurance field in China. This initiative underscores the government’s commitment to safeguarding the integrity…
-
Johnson & Johnson’s Kenvue IPO Raises USD 3.8 Billion, Marking Year’s Largest US IPO
•
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced the initial public offering (IPO) of 173 million shares by its consumer health spin-off company Kenvue to the New York Stock Exchange (NYSE), raising a staggering USD 3.8 billion. This transaction has secured its place as the biggest IPO…
-
Full-Life Technologies Ltd to Establish GMP-Compliant Radiopharmaceutical Plant in Belgium’s Wallonie Region
•
Shanghai-headquartered Full-Life Technologies Ltd has announced a significant land acquisition deal in the Wallonie region of Belgium, with the aim of establishing a Good Manufacturing Practice (GMP)-compliant advanced radiopharmaceutical plant. This strategic move is set to bolster the company’s position in the radiation therapy sector. Addressing Manufacturing Challenges in Radiation…
-
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
•
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over the quarter. AstraZeneca’s China Innovation BoomAstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot warned that Europe is lagging behind China in fostering innovation and access to medicines. This statement came during the company’s Q1 2023 earnings…
-
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
•
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (ANG2) for intravitreal injection in the treatment…
